Table 2.
Groups | SOD/U•mg−1 | CAT/U•mg−1 | GSH-Px/U•mg−1 | MDA/nmol•mg−1 |
---|---|---|---|---|
sham | 795.05 ± 79.26 | 85.61 ± 9.02 | 214.71 ± 18.45 | 1.74 ± 1.34 |
I/R injury | 530.45 ± 46.86* | 32.73 ± 3.28* | 127.11 ± 13.75* | 29.71 ± 1.36* |
NC | 531.54 ± 46.77* | 31.83 ± 3.05* | 127.55 ± 14.73* | 29.52 ± 1.56* |
miR-202-3p mimic | 661.32 ± 57.56*# | 53.11 ± 7.18*# | 170.51 ± 18.58*# | 15.86 ± 1.02*# |
siRNA-TRPM6 | 671.31 ± 56.89*# | 53.16 ± 6.02*# | 171.34 ± 19.57*# | 15.45 ± 1.21*# |
miR-202-3p inhibitor | 366.62 ± 36.83*# | 12.04 ± 1.03*# | 82.11 ± 10.26*# | 43.88 ± 3.93*# |
miR-202-3p inhibitor + siRNA-TRPM6 | 531.43 ± 46.61* | 32.96 ± 3.26* | 126.88 ± 12.15* | 29.48 ± 1.87* |
*, p < 0.05 vs. the sham group; #, p < 0.05 vs. the I/R injury group; n = 5; multiple groups were compared by one-way analysis of variance followed by a Tukey’s post hoc test; NC, negative control; miR-202-3p, microRNA-202-3p; TRPM6, transient receptor potential cation channel, subfamily M, member 6; SOD, superoxide dismutase; CAT, catalase; GSH-Px, glutathione peroxidase; MDA, malondialdehyde.